drugset / Trial / NCT00002269
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
Completed
HEM Research
Double-blindTreatment
Summary
To evaluate ampligen at two dosage levels given twice weekly in combination with zidovudine (AZT) versus AZT alone in individuals with HIV-related immune dysfunction defined as T4 count between 100 and 300 cells/mm3.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rintatolimod | Oligonucleotide (other) | — | — |
| Background | Zidovudine | Small molecule | — | — |